2005
DOI: 10.1602/neurorx.2.4.554
|View full text |Cite
|
Sign up to set email alerts
|

Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery

Abstract: Summary:The worldwide market for therapies for CNS disorders is worth more than $50 billion and is set to grow substantially in the years ahead. This is because: 1) the incidence of many CNS disorders (e.g., Alzheimer's disease, stroke, and Parkinson's disease) increase exponentially after age 65 and 2) the number of people in the world over 65 is about to increase sharply because of a marked rise in fertility after World War II. However, CNS research and development are associated with significant challenges:… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
256
0
4

Year Published

2012
2012
2016
2016

Publication Types

Select...
5
4

Relationship

1
8

Authors

Journals

citations
Cited by 402 publications
(272 citation statements)
references
References 85 publications
2
256
0
4
Order By: Relevance
“…26 AD is the most common form of dementia, and the greatest risk factor for AD is age. It is estimated that 10% of people over the age of 65 are affected by AD 4 and by 2050, the number of people with AD in the US will increase threefold. 45 The definite diagnosis of AD is made upon histological verification, established by biopsy or at autopsy, of two main hallmarks: extracellular amyloid plaques and intracellular neurofibrillary tangles, which enclose hyperphosphorylated tau protein.…”
Section: Alzheimer Diseasementioning
confidence: 99%
See 1 more Smart Citation
“…26 AD is the most common form of dementia, and the greatest risk factor for AD is age. It is estimated that 10% of people over the age of 65 are affected by AD 4 and by 2050, the number of people with AD in the US will increase threefold. 45 The definite diagnosis of AD is made upon histological verification, established by biopsy or at autopsy, of two main hallmarks: extracellular amyloid plaques and intracellular neurofibrillary tangles, which enclose hyperphosphorylated tau protein.…”
Section: Alzheimer Diseasementioning
confidence: 99%
“…Estimates state that 1% of people over age 60 are affected by PD, the leading cause of the movement disorder called Parkinsonism. 4 Clinical features of PD include tremor at rest, bradykinesia, rigidity and flexed posture. 48 Pathologically, the key deficit in PD has been considered to be the loss of dopaminergic neurons in the substantia nigra, which causes consequent reduction of dopamine level.…”
Section: Parkinson Diseasementioning
confidence: 99%
“…44 On the other hand, neutral compounds with a polar surface area (PSA) lower that 60 Å 2 and molecular mass below 450 Da have better permeation possibility. [45][46][47] Another enzyme similar to AChE is butyrylcholinesterase (BChE), which displays about 65% of amino acid sequence similarity with AChE. 48 However, while AChE is involved in the control of nerve pulse transition by hydrolysis of acetylcholine in cholinergic synapses, BChE performs actions in pharmacological and toxicological processes by hydrolysis of drugs containing ester groups and some AChE inhibitors.…”
Section: Introductionmentioning
confidence: 99%
“…In order to improve the understanding of drug efficacy and safety characteristics, it is desirable to investigate the drug metabolism in animals or humans [3,4]. These metabolism studies involve metabolic stability, cytochrome P-450 (CYP-450) induction or inhibition and metabolite identification.…”
Section: Editorialmentioning
confidence: 99%